CompletedNCT00402584
Sibutramine to reduce binge eating
About this title
A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder
Read the official source — NCT00402584Medication studyAges 18–65Eating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2000
- Recruitment status
- Completed
- Enrollment listed in the registry
- 304
- Sponsor
- Abbott
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Not clearly listed
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00402584
- Official title
Show the full official title
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Examine the Efficacy and Safety of Meridia (Sibutramine Hydrochloride) in Binge-Eating Disorder
Get this study by email
Recruitment & locations
CompletedLocations not listed
Questions about this study
Who is behind this study?
The study sponsor is Abbott.
Did this study involve medication?
Yes. The study involved medication, including sibutramine.
Who was this study for?
Listed age limits: 18 years to 65 years.
